5 (128.9) 21.4% 256.5 (116.6) 292.5 (132.9) 14.0% 0.019 RTF (total)** 19.6 30.25 54.3% 26.3 30.8 17.1% 0.004 Body Fat % 16.8 15.5 -7.7% 16.5 16.9 2.4% 0.028 Lean Mass (kg) 62.7 64.2 Palbociclib 2.4% 62.6 62.8 0.3% 0.049 Body Weight (kg) 81.1 80.8 -0.2% 79.9 80.2 0.2% 0.22 Fat Mass (kg) 13.5 12.2 -9.6% 13.3 13.8 3.8% 0.023 *Via ANCOVA **RTF (total) represents a sum of the 3 sets of bench press Figure 2 ANCOVA for 1 Repetition

Maximum Bench Press (1 RM). The 1 RM for the SOmaxP cohort increased from 233.5-283.5 lbs. [106.1-128.9 kg] from pre- to post-testing (21.4% increase), while the CP cohort increased from 256.5-292.5 lbs. [116.6-132.9 kg], (14.0% increase). The RTF for the SOmaxP cohort increased from 19.6 to 30.25 from pre- to post-testing (54.3% increase), while the CP cohort increased from 26.3 to 30.8 (17.1% increase). Several measures of body composition differed statistically between the two cohorts, with the SOmaxP cohorts demonstrating favorable improvements. The body fat percentage in the SOmaxP group decreased from 16.8% to 15.5% from pre- to post-testing (7.7% decrease), while

the CP cohort increased slightly from 16.5% to 16.9% (2.4% increase). Lean body mass increased in the SOmaxP group from 62.7 kg to 64.2 kg (2.4% increase), while the CP cohort increased marginally from 62.6 kg to 62.8 kg (0.3% increase). Body weight did not change JQ-EZ-05 significantly in either group, with the SOmaxP group experiencing a drop of 1.5 kg from a baseline of 81.1 kg to ADP ribosylation factor 80.8 kg (0.2 kg decrease), while the CP cohort gained 1.5 kg from a baseline of 79.9 kg to 80.2 kg (0.2 kg increase). Finally, in the SOmaxP cohort, fat mass decreased from 13.5 kg to 12.2 kg (9.6% decrease), while the CP cohort increased from 13.3 kg to 13.8 kg (3.8% increase). The percentage change from baseline (Post minus Pre × 100) in strength measures (RTF(t)

and 1-RM) are presented in Figure 7 below, and PND-1186 concentration similar changes in body composition measures (lean mass, body fat percentage and fat mass) are presented in Figure 8. Figure 7 Percentage Change from Baseline (Post minus Pre × 100) in Strength Measures. Figure 8 Percentage Change from Baseline (Post minus Pre × 100) in Body Composition Measures. There were no clinically meaningful changes in vital signs or laboratory results from baseline to Week 9. One subject experienced an adverse event. The subject was a 20 year-old male, (SOmaxP group) who experienced seasonal flu symptoms during Week 8 of the study. Symptoms included nausea, vomiting, and decreased appetite, and the events were not assessed as related to study product. Symptoms were resolved at the Week 9 post-testing visit.